The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

Inclusion Criteria:

• Are currently receiving olaratumab and who, in consultation with their treating physician, want to continue their course of therapy.
• Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.
• Have given written informed consent.
• Have an absolute neutrophil count (ANC) ≥1,000/microliter.
• Females of childbearing potential and males must agree to use highly effective contraceptive precautions during treatment with olaratumab and up to 3 months following the last dose of olaratumab. A highly effective method of birth control is defined as one that results in a low failure rate (that is, <1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.

Exclusion Criteria:

• Breastfeeding (patients who discontinue breastfeeding would be considered eligible).